TORONTO and HOUSTON, TX, Sept. 6,
2017 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or the "Company") (TSX: MDNA), a
clinical stage immuno-oncology company, today announced that Dr.
Fahar Merchant, Chairman, President
and Chief Executive Officer will be presenting at the Rodman &
Renshaw 19th Annual Global Investment Conference sponsored by
H.C. Wainwright & Co.,
LLC. in New York City on
Tuesday, September 12th, at
4:15 PM Eastern Standard Time at the
Lotte New York Palace Hotel. Medicenna is currently enrolling
patients in a Phase 2b trial of MDNA55 for recurrent glioblastoma
(rGB), the most common and uniformly fatal form of brain
cancer.
Dr. Merchant will provide a corporate overview of the Company's
recent activities and strategic direction and will be available
along with Elizabeth Williams,
Medicenna's Chief Financial Officer, for one-on-one meetings from
September 10 – 12, 2017.
Presentation details:
Time:
|
|
|
|
|
4:15 p.m.
ET
|
Date:
|
|
|
|
|
Tuesday, September
12, 2017
|
Location:
|
|
|
|
|
Lotte New York Palace
Hotel, New York, NY
|
A live webcast of the Medicenna presentation will be accessible
by visiting:
http://wsw.com/webcast/rrshq27/mdna/
The webcast will be archived shortly after the live event and
will be available for 90 days through the Medicenna website
at www.medicenna.com
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing
novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™
and first in class Empowered Cytokines™ (ECs). Its wholly
owned subsidiary, Houston-based Medicenna BioPharma, is
specifically targeting the Interleukin-4 Receptor (IL4R), which is
over-expressed by at least 20 different types of cancer affecting
more than one million new cancer patients every year. Medicenna's
lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical
trial for rGB at leading brain cancer centres in the US. MDNA55 has
completed 3 clinical trials in 72 patients, including 66 adults
with rGB, demonstrated compelling efficacy and obtained Fast-Track
and Orphan Drug status from USFDA. Unlike most other cancer
therapies, Medicenna's IL4-ECs have the potential to purge both the
tumor and the immunosuppressive tumor microenvironment, offering a
unique treatment paradigm for a large majority of cancer
patients.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
future plans and objectives of the Company and others are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Important
factors that could cause actual results to differ materially from
the Company's expectations include the risks detailed in the annual
information form of the Company dated June
15, 2017 and in other filings made by the Company with the
applicable securities regulators from time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.